Original Articles

622 Receptor Expression Discrepancy between Primary and Metastatic Breast Cancer Lesions

628 Ductoscopic Detection of Intraductal Lesions in Cases of Pathologic Nipple Discharge in Comparison with Standard Diagnostics: The German Multicenter Study
Ohlinger, R.; Stomps, A. (Greifswald); Paepke, S. (Munich); Blohmer, J.; Grunwald, S.; Hahndorf, W. (Greifswald); Camara, O.; Deichert, U.; Peisker, U.; Kohlmann, T.; Buchholz, I.; Hegenscheid, K.; Utpatel, K.; Zygmunt, M. (Greifswald); Hahn, M. (Tübingen)

635 Treatment of Non-Transplant Patients with Multiple Myeloma: Routine Treatment by Office-Based Haematologists in Germany – Data from the Prospective Tumour Registry Lymphatic Neoplasms (TLN)
Knauf, W. (Frankfurt/M.); Abenhardt, W. (Munich); Aidaoud, A. (Leipzig); Nusch, A. (Velbert); Grugel, R.; Münz, M.; Hartmann, H.; Marschner, N. (Freiburg i.Br.); TLN Study Group

646 Efficacy of Triplet Combination Chemotherapy with Oxaliplatin, Irinotecan and Capecitabine (OCX) in Metastatic Colorectal Cancer in Relation to RAS/RAF Mutation Status: Results of a Retrospective Analysis
Brunner, S.; von Moos, R.; Mey, U. (Chur); Camenisch Gross, U. (Zurich); Freyholdt, T.; Cathomas, R. (Chur)

654 The Functional SNP rs3746804 in C20orf54 Modifies Susceptibility to Esophageal Squamous Cell Carcinoma
Ji, A.; Ma, L.; Yang, J.; Xu, J.; Wang, J.; Lian, C.; Wang, Y.; Li, D. (Changzhi); Dong, W-L. (Zhengzhou); Wei, W. (Changzhi)

658 miRNA-205 Is a Candidate Tumor Suppressor that Targets ZEB2 in Renal Cell Carcinoma
Chen, Z.; Tang, Z.; He, Y.; Liu, L-F.; Li, D.; Chen, X. (Changsha)

666 ABCG2-Mediated Multidrug Resistance and Tumor-Initiating Capacity of Side Population Cells from Colon Cancer
Novel Insights from Clinical Practice

674 Treatment of Malignant Ascites with a Second Cycle of Catumaxomab in Gastric Signet Cell Carcinoma – a Report of 2 Cases
Thomaidis, T.; Wörns, M.; Galle, P.; Mohler, M.; Schattenberg, J. (Mainz)

679 Reports of Oncological Societies
683 PharmaForum
689 PharmaNews / PharmaTicker
695 Meetings and Conferences
700 Guidelines for Authors
678 Imprint
Guidelines for Authors

Submission

ONCOLOGY RESEARCH AND TREATMENT is a peer-reviewed journal intended to provide a forum for presentation of all aspects of oncology, including reviews and original articles from hematology and medical oncology, surgical, gynecological and urological oncology, radiation therapy as well as clinical-experimental oncology. Contributions to pediatrics, ENT and dermatological oncology, pathology, biometry, epidemiology, prevention, early diagnosis and psychological care will also be considered. Manuscripts must be submitted online: www.karger.com/ort.

Should you have any problems with electronic submission please contact the Editorial Office:

S. Karger Verlag für Medizin und Naturwissenschaften GmbH
Attn.: Dr. Steffi Hentzelt
P.O. Box 70092 Freiburg (Germany)
Tel. +49 761 45 20 725
Fax +49 761 45 20 714
s.hentzelt@karger.com

Language

All contributions must be written in English (American or British spelling and grammar).

Types of Papers and Allotted Number of Pages

Please print the manuscript 1 1/2-spaced with 3-cm margins (left and right). Use only one format (normal) for the document.

The text (including the summary) should be limited to the following number of pages:

<table>
<thead>
<tr>
<th>Type of Paper</th>
<th>Printed Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Review Article, Original Article</td>
<td>5</td>
</tr>
<tr>
<td>Novel Insights from Clinical Practice</td>
<td>3</td>
</tr>
<tr>
<td>Ongoing Clinical Trial, Oncological Education, Clinical Information</td>
<td>4</td>
</tr>
<tr>
<td>Letter to the Editor</td>
<td>1</td>
</tr>
<tr>
<td>Others</td>
<td>12,000</td>
</tr>
</tbody>
</table>

*including title page, summary, illustrations, tables, and references. Tables and figures count for 1,500 characters each. Each additional complete or partial page to print will be charged to the author.

Novel Insights from Clinical Practice (formerly Case Report): The journal only considers case reports with significant new insights or with an extremely unusual and memorable course. The most important aspect of the presentation is that it should provide a new perspective on a recognized clinical scenario or may represent an entirely new clinical condition. Highlighted boxes containing one or two bullet points on 'Established facts' (what is already known) and 'Novel insights' (what new information has been gained) are required and should be placed on the first page of the report. These should highlight the novelty of the clinical observation. The manuscript should be presented with an abstract (max. 200 words), followed by introduction, case report and discussion.

Conditions

Acceptance of a manuscript is based on the evaluation by several reviewers (peer review). Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Once the manuscript is accepted for publication, all usage rights will be retained by the publisher. The assignment of usage rights applies to all print media as well as electronic offline and online media, including the Internet and data bases/data carriers of any kind. Accepted papers, in whole or in part, may not be translated into other languages, or reproduced by any mechanical or electronic means (including photocopying, recording and microcopying), or stored in a retrieval system without the written consent of the publisher. The assignment of usage rights applies to all print media as well as electronic offline and online media, including the Internet and data bases/data carriers of any kind. Accepted papers, in whole or in part, may not be translated into other languages, or reproduced by any mechanical or electronic means (including photocopying, recording and microcopying), or stored in a retrieval system without the written consent of the publisher. The publisher reserves the right to edit the manuscript and decide on the layout.

Disclosure Statement

Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Disclosure statements will be published at the end of the text of the article.

Ethical and Legal Prerequisites

Manuscripts involving examinations of human subjects must include a statement that the trial protocol has been approved by an ethical committee and thus meets the standards of the Declaration of Helsinki in its revised version of 1975 and its amendments of 1983, 1989, and 1996 [JAMA 1997;277:925–926]. Accordingly, the subject’s informed consent has to be mentioned in the manuscript. Information suitable to reveal the subject’s identity is to be avoided.

Plagiarism Policy

Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation.

If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Arrangement

Title page: The first page of each paper should indicate the title and a short title for use as running head.

Authors’ affiliations and address of correspondence: Each author’s full name, followed by their affiliation (hospital, institute etc. where the work was conducted) and the exact postal address of the corresponding author complete with postal code must be given. Please also supply phone and fax numbers, as well as e-mail address.

Key Words: For indexing purposes, a list of 3-5 key words is essential. Whenever possible, use key words such as found in the Medical Subject Headings List (MeSH) of Index Medicus.

Summary: The summary must not exceed 200 words. Summaries of Original Articles and Case Reports should be structured as follows: Background (or Introduction), Patients and Methods (or Material and Methods), Results, Conclusion.

Footnotes: Footnotes should be used only for tables.

Registered Trade Names: When first mentioned, registered trade names must be marked with the superscript registration symbol '®' or '™'. It is the sole responsibility of the author to ensure that this rule is followed properly.

Tables and Illustrations: Tables and illustrations should be prepared on separate pages. Tables require a heading and figures a legend. The number of figures and tables should be limited and aim to illustrate the text. Figures are listed in the text as (fig. 1), tables as (table 1). Data already mentioned in the text need not be repeated in a table. Accordingly, numbers used in tables need not be repeated in the text.

Electronically submitted bw/half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 600 dpi.

Color illustrations are reproduced at the author’s expense. Each one is charged to the author at EUR 300.00 + VAT as contribution to the additional reproduction and color printing costs.

References

The list of references should include only the publications cited in the text. The list should not exceed 60 references for reviews.

References must be numbered sequentially in the order cited in the text. In the text identify references by Arabic numerals [in square brackets]. Preferably please cite all authors.

It is recommended to quote only articles already published or accepted for publication. Please avoid ‘in preparation’ or ‘personal communication’.

Authors are responsible for the accuracy and completeness of their references and for correct citation.

Journal titles should be abbreviated according to the Index Medicus system (www.nlm.nih.gov). If a reference manager is used, the style ‘Pharmacology’ or ‘Nephron’ should be chosen.

Examples for references can be found at www.karger.com/ort_gl.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Page Charges

There are no page charges for papers that do not exceed the allotted size (cf. types of papers). Each additional complete or partial page is charged to the author at 400.00 EUR + VAT.

Proofs

Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer’s errors, are charged to the author. No page proofs are supplied.

Reprints

Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.